Leukocare grants technology license to US vaccine company PaxVax

Privately-held California, USA-based specialty vaccine firm PaxVax has been granted a license to Germany-based Leukocare’s proprietary SPS formulation technology platform for the clinical development and subsequent commercialization of one of PaxVax's live viral vaccine products.

The licensing agreement provides PaxVax with exclusive access to two product-specific pharmaceutical formulations based on Leukocare’s Stabilizing and Protecting Solutions (SPS®) formulation platform. The undisclosed live adenovirus-based vaccine candidate will enter clinical trials by early 2017. Under the terms of the agreement, Leukocare will receive milestone payments and annual license fees during development and undisclosed royalties on net sales during commercialization of the vaccine. Further financial terms were not disclosed.

"For the entire pre-clinical development phase of the product Leukocare has been a reliable partner in supporting our efforts to develop stabilizing formulations for our adenovirus-based vaccine. We are very pleased that the product will soon enter clinical trials", said Jonathan Smith, chief scientific officer of PaxVax.